Aligos Therapeutics, Inc. ALGS
Aligos Therapeutics, Inc. (Nasdaq: ALGS) is an infectious disease drug developer. Its lead program, pevifoscorvir sodium (ALG-000184), is in Phase 2 for chronic hepatitis B virus infection. Its next catalyst on record is ALG-170675: Start of chronic HBV cohort after 150 mg MAD cohort (Q4 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: ALG-170675 — Start of chronic HBV cohort after 150 mg MAD cohort (Q4 2026). 3 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| pevifoscorvir sodium (ALG-000184) | chronic HBV infection | small molecule | Phase 2 |
| ALG-055009 | MASH / obesity | small molecule | Phase 2 |
| ALG-097558 | coronavirus infections / COVID-19 | small molecule | Phase 2 |
| ALG-170675 | chronic HBV infection | oligonucleotide-other | Pre-clinical |
Recent results and decisions
- Apr 14, 2026n/a First interim analysis: DSMB recommended continuing and raising HBeAg- cohort (Part 2a) from 74 to 100 participants; futility criteria not met; well tolerated; no efficacy data disclosed.
A futility analysis was performed; the prespecified futility criteria was not met, per the statistical analysis plan.
Filing - Apr 14, 2026n/a FDA granted Fast Track Designation to pevifoscorvir sodium for chronic HBV infection.
Aligos announced that the United States Food and Drug Administration (FDA) has granted Fast Track Designation to pevifoscorvir sodium
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 infectious disease companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.